ERBB2 and breast carcinoma: Among RTK-targeting bispecific ADCs, anbenitamab repodatecan (Park et al., 2024) and TQB2102 (Li J et al., 2025) have been used in randomized phase III clinical trials for HER2-positive breast cancer patients (NCT06846437 and NCT06561607, respectively), and izalontamab brengitecan (Ma et al., 2024) has been assessed in phase III clinical trials for patients with nasopharyngeal carcinoma (NCT06118333), lung cancer (NCT06382116 and NCT06500026) and other types of cancers (NCT06304974, NCT06343948, NCT06382142 and NCT06857175).